发布求助
文献互助 智能选刊 最新文献

Immunotherapy最新文献

筛选
英文 中文
Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies. 原发性免疫缺陷病的免疫球蛋白疗法（第二部分）：剂量策略的注意事项。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-09-26 DOI: 10.1080/1750743X.2024.2382074
Zhaoyang Li, Iftekhar Mahmood
{"title":"Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies.","authors":"Zhaoyang Li, Iftekhar Mahmood","doi":"10.1080/1750743X.2024.2382074","DOIUrl":"10.1080/1750743X.2024.2382074","url":null,"abstract":"<p><p>Immunoglobulin G (IgG) dosing in treating primary immunodeficiency diseases (PIDs) is individualized, which often involves regular monitoring of IgG levels, and considers patient experiences with immunoglobulin therapies, their clinical status and physician judgment. The frequency and dose(s) of intravenously (IVIG) and subcutaneously (SCIG) administered IgGs (including hyaluronidase-facilitated SCIG) require rigorous evaluation to maximize therapeutic benefits. Monitoring serum IgG levels represents an integral part of diagnosing primary immunodeficiency diseases and determining or adjusting IgG dosing strategies to meet individual patient needs, but cannot be conducted in isolation. This review discusses the current state and future perspectives on dosing strategies for different types of IgG therapies, as well as dosing considerations for specific patient populations, immunoglobulin-naive patients and patients switching between IVIG and SCIG.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":"16 13","pages":"895-905"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142345786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The development of anti-PD-1 antibody-induced spinal cord injury in bone marrow transplant C57BL/6 Rag1-/- mouse model. 骨髓移植 C57BL/6 Rag1-/- 小鼠模型中抗 PD-1 抗体诱导的脊髓损伤的发展。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-08-08 DOI: 10.1080/1750743X.2024.2383557
Huachun Chen, Zhouxiao Lu, Xiaowei Ni, Hui Zhang, Guiyuan Chen, Xiaoyu Wu, Mingxing Ding
{"title":"The development of anti-PD-1 antibody-induced spinal cord injury in bone marrow transplant C57BL/6 <i>Rag1<sup>-/-</sup></i> mouse model.","authors":"Huachun Chen, Zhouxiao Lu, Xiaowei Ni, Hui Zhang, Guiyuan Chen, Xiaoyu Wu, Mingxing Ding","doi":"10.1080/1750743X.2024.2383557","DOIUrl":"10.1080/1750743X.2024.2383557","url":null,"abstract":"<p><p><b>Aims:</b> This paper was to scrutinize the toxicity mechanism of anti-programmed death 1 (anti-PD-1) therapy-caused spinal cord injury (SCI).<b>Methods:</b> Bone marrow transplant <i>Rag1<sup>-/-</sup></i> mice were used to establish SCI model.<b>Results:</b> Anti-PD-1 results in SCI via CD8<sup>+</sup> T-cells activation, while excessive activation of CD8<sup>+</sup> T-cells further aggravated SCI. Both anti-PD-1 and the activation of CD8<sup>+</sup> T-cells induced the expression of apoptosis-related perforin, GrB and FasL, but suppressed PI-9 level. The opposite results were observed in the effects of neuroserpin on these factors. CD8<sup>+</sup> T-cells activation induced neurotoxicity via upregulation perforin, GrB and FasL and inhibiting PI-9. Additionally, neuroserpin suppressed CD8<sup>+</sup> T-cells activation via perforin/GrB/PI-9/FasL pathways.<b>Conclusion:</b> These results may provide theoretical foundation for the clinical treatment of SCI caused by anti-PD-1.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"975-985"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy and transarterial embolization in patients with metastatic melanoma: a retrospective cohort study. 转移性黑色素瘤患者的免疫疗法和经动脉栓塞治疗：一项回顾性队列研究。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-09-03 DOI: 10.1080/1750743X.2024.2382665
Leila Haghani, Chenyang Zhan, Hooman Yarmohammadi, Etay Ziv, Vlasios S Sotirchos, Debkumar Sarkar, Alexander N Shoushtari, Joseph P Erinjeri
{"title":"Immunotherapy and transarterial embolization in patients with metastatic melanoma: a retrospective cohort study.","authors":"Leila Haghani, Chenyang Zhan, Hooman Yarmohammadi, Etay Ziv, Vlasios S Sotirchos, Debkumar Sarkar, Alexander N Shoushtari, Joseph P Erinjeri","doi":"10.1080/1750743X.2024.2382665","DOIUrl":"10.1080/1750743X.2024.2382665","url":null,"abstract":"<p><p><b>Aim:</b> To investigate how the sequence of checkpoint immunotherapy (CPI) and transarterial embolization (TAE) affects overall survival (OS) of patients with metastatic melanoma.<b>Materials & methods:</b> This retrospective cohort study included 65 patients with metastatic melanoma who underwent both TAE and CPI between September 2011 and January 2022.<b>Results:</b> Significantly higher OS was seen in patients who received CPI before and after embolization (22 months, 95% CI 14-NR, <i>p</i> < 0.001) compared with only before embolization (4.5 months 95% CI, 14-NR). ≤3 hepatic metastasis (<i>p</i> < 0.01), more TAE procedures (<i>p</i> < 0.001) and CPI sequence (before and after embolization) (<i>p</i> < 0.001) were independent predictors of survival.<b>Conclusion:</b> Metastatic melanoma patients who underwent TAE have longer survival when CPI was sequenced both before and after embolization.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"955-962"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study. 透明质酸酶促进皮下注射 10%免疫球蛋白的长期安全性：欧洲授权后研究。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1080/1750743X.2024.2354091
Pauline M Ellerbroek, Leif G Hanitsch, Torsten Witte, Vassilios Lougaris, P Martin van Hagen, Pieter van Paassen, Jie Chen, Katharina Fielhauer, Barbara McCoy, Andras Nagy, Leman Yel
{"title":"Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study.","authors":"Pauline M Ellerbroek, Leif G Hanitsch, Torsten Witte, Vassilios Lougaris, P Martin van Hagen, Pieter van Paassen, Jie Chen, Katharina Fielhauer, Barbara McCoy, Andras Nagy, Leman Yel","doi":"10.1080/1750743X.2024.2354091","DOIUrl":"10.1080/1750743X.2024.2354091","url":null,"abstract":"<p><p><b>Aim:</b> To assess the long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% in European routine clinical practice.<b>Materials & methods:</b> This prospective, noninterventional, open-label, post-authorization safety study (EUPAS5812) sourced data on adverse events, immunogenicity, treatment regimens and product administration for 106 adult patients prescribed fSCIG 10% across 17 sites in six European countries from July 2014 to February 2020.<b>Results:</b> In total, 1171 treatment-emergent adverse events were reported in 94 patients (88.7%); 25.5% of these events were considered related to fSCIG 10%. Positive binding antibody titers developed in three patients; no neutralizing antibodies to recombinant human hyaluronidase were detected.<b>Conclusion:</b> This real-world study of fSCIG 10% is the longest to date and confirms its long-term safety and tolerability in adults with antibody deficiency diseases.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"679-691"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis. 外周血细胞因子与免疫检查点阻断疗法的疗效：系统综述与荟萃分析。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1080/1750743X.2024.2379230
Alexander B Karol, Yu Fujiwara, Tyler D'Ovidio, Elena Baldwin, Himanshu Joshi, Deborah B Doroshow, Matthew D Galsky
{"title":"Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis.","authors":"Alexander B Karol, Yu Fujiwara, Tyler D'Ovidio, Elena Baldwin, Himanshu Joshi, Deborah B Doroshow, Matthew D Galsky","doi":"10.1080/1750743X.2024.2379230","DOIUrl":"10.1080/1750743X.2024.2379230","url":null,"abstract":"<p><p><b>Background:</b> Tumor-promoting inflammation and inflammatory cytokines are linked to immune checkpoint blockade (ICB) resistance.<b>Methods:</b> We assessed the associations between pre-treatment Interleukin-6 (IL-6), Interleukin-8 (IL-8) levels and on-treatment changes in IL-6, IL-8 and C-reactive protein (CRP) with ICB trial end points.<b>Results:</b> 27 studies representing 6,719 patients were included. Low pre-treatment IL-6 levels were associated with improved objective response rate (ORR) (odds ratio (OR) = 0.31 [0.18-0.55]) and better progression-free survival (PFS) (hazard ratio (HR) = 0.59 [0.48-0.72]) and overall survival (OS) [95% confidence interval (CI)] (HR = 0.42 [0.35-0.50]). Low pre-treatment IL-8 levels were associated with improved ORR (OR = 0.47 [0.36-0.61]) and better PFS (HR = 0.65 [0.58-0.74]) and OS (HR = 0.44 [0.39-0.51]). On-treatment decline in CRP was associated with improved ORR (OR = 0.18 [0.11-0.20]), PFS (HR = 0.40 [0.31-0.91]) and OS (HR = 0.48 [0.40-0.58]).<b>Conclusion:</b> Peripheral blood cytokines warrant further evaluation as enrichment and pharmacodynamic biomarkers for strategies targeting tumor-promoting inflammation.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"829-840"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bioengineering MSCs for untapped therapeutic potential. 生物工程间充质干细胞尚未开发的治疗潜力。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-09-13 DOI: 10.1080/1750743X.2024.2390819
Olivia Sirpilla, Saad S Kenderian
{"title":"Bioengineering MSCs for untapped therapeutic potential.","authors":"Olivia Sirpilla, Saad S Kenderian","doi":"10.1080/1750743X.2024.2390819","DOIUrl":"10.1080/1750743X.2024.2390819","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"907-911"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142286112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A lesson from fatal invasive fungal infections after CAR-T cell therapy: a case report and literature review. CAR-T细胞疗法后致命性侵袭性真菌感染的教训：病例报告和文献综述。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-10-07 DOI: 10.1080/1750743X.2024.2404381
Zhengfeng Hou, Danchen Meng, Min Ruan, Xinglin Liang, Jing Ni, Dai Jifei, Zhonghui Wu, Ruixiang Xia, Jian Ge, Zhangbiao Long
{"title":"A lesson from fatal invasive fungal infections after CAR-T cell therapy: a case report and literature review.","authors":"Zhengfeng Hou, Danchen Meng, Min Ruan, Xinglin Liang, Jing Ni, Dai Jifei, Zhonghui Wu, Ruixiang Xia, Jian Ge, Zhangbiao Long","doi":"10.1080/1750743X.2024.2404381","DOIUrl":"10.1080/1750743X.2024.2404381","url":null,"abstract":"<p><p>CD19 chimeric antigen receptor T (CAR-T) cell therapy represents an effective approach to treating patients with relapsed or refractory B-cell hematologic malignancies. Nevertheless, owing to the immunosuppressive effects of this regimen, patients undergoing CD19 CAR-T cell therapy may face an elevated risk of invasive fungal infections, which involve fungi penetrating the host's tissues or bloodstream, leading to life-threating infectious diseases. Herein, we present the case of a 17-year-old male diagnosed with acute lymphoblastic leukemia, who subsequently experienced a fatal invasive fungal infection following administration of CAR-T cell therapy. Furthermore, we delve into the identification of risk factors, implementation of preventive measures and exploration of therapeutic interventions for invasive fungal infections after CAR-T cell therapy.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1021-1027"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy. 中性粒细胞与淋巴细胞比率对接受免疫疗法的晚期癌症患者血脂状况的不同影响。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-08-06 DOI: 10.1080/1750743X.2024.2377953
Fabiana Perrone, Federica Pecci, Michele Maffezzoli, Giulia Claire Giudice, Valeria Cognigni, Giulia Mazzaschi, Luca Cantini, Luca Santamaria, Francesco Paoloni, Marco Luigi Bruno Rocchi, Matilde Coriano', Alessandro Acunzo, Federico Quaini, Marcello Tiseo, Saini S Kamal, Rossana Berardi, Sebastiano Buti
{"title":"Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy.","authors":"Fabiana Perrone, Federica Pecci, Michele Maffezzoli, Giulia Claire Giudice, Valeria Cognigni, Giulia Mazzaschi, Luca Cantini, Luca Santamaria, Francesco Paoloni, Marco Luigi Bruno Rocchi, Matilde Coriano', Alessandro Acunzo, Federico Quaini, Marcello Tiseo, Saini S Kamal, Rossana Berardi, Sebastiano Buti","doi":"10.1080/1750743X.2024.2377953","DOIUrl":"10.1080/1750743X.2024.2377953","url":null,"abstract":"<p><p><b>Aim:</b> To investigate the different impact of each component of lipid profile in advanced cancer patients treated with immune checkpoints inhibitors (ICIs) according to neutrophil-to-lymphocyte ratio (NLR) value.<b>Methods:</b> We retrospectively collected total cholesterol (TC), triglycerides (TGs), low-density lipoproteins (LDL), high-density lipoproteins (HDL).<b>Results:</b> 407 patients were enrolled. In NLR <4 subgroup, TGs <150 mg/dl led to longer PFS (<i>p</i> = 0.01) and OS (<i>p</i> = 0.02) compared with TGs ≥150 mg/dl; LDL <100 mg/dl led to longer PFS (<i>p</i> = 0.004) and OS (<i>p</i> = 0.007) compared with LDL ≥100 mg/dl. In NLR ≥4 subgroup, TC >200 mg/dl led to longer PFS (<i>p</i> = 0.008) and OS (<i>p</i> = 0.004) compared with TC <200 mg/dl.<b>Conclusion:</b> We showed a distinct prognostic impact of lipid profile according to NLR.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"859-868"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy. 托西珠单抗和CytoSorb用于治疗伊匹单抗加尼伐单抗免疫疗法后的延迟性严重细胞因子释放综合征。
IF 2.7 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-07-17 DOI: 10.1080/1750743X.2024.2370180
Marko Kurnik, Fazarinc Peter, Podbregar Matej
{"title":"Tocilizumab and CytoSorb for delayed severe cytokine release syndrome after ipilimumab plus nivolumab immunotherapy.","authors":"Marko Kurnik, Fazarinc Peter, Podbregar Matej","doi":"10.1080/1750743X.2024.2370180","DOIUrl":"10.1080/1750743X.2024.2370180","url":null,"abstract":"<p><p>Cytokine release syndrome (CRS) is immune dysregulation phenomenon that is associated with immune checkpoint inhibitors. It is still difficult to distinguish CRS from other dangerous, acute and life-threatening medical disorders.We present a case of delayed grade 4 CRS following treatment of lung adenocarcinoma with ipilimumab plus nivolumab that warranted intensive care level treatment with abundant fluid resuscitation, two-tire vasopressor support, high-flow nasal oxygenation, corticosteroids in high dosages, as well as sustained low-efficiency daily diafiltration with CytoSorb hemadsorption and tocilizumab. Initial treatment of presumed septic shock of unknown origin did not yield results.After initiation of corticosteroids and particularly CytoSorb hemadsorption and tocilizumab, prompt clinical and laboratory improvement was observed.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"791-801"},"PeriodicalIF":2.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Welcome to Immunotherapy Volume 16! 欢迎阅读《免疫疗法》第 16 卷！
IF 2.8 4区 医学
Immunotherapy Pub Date : 2024-01-01 Epub Date: 2023-12-06 DOI: 10.2217/imt-2023-0309
Rebecca Turner
{"title":"Welcome to <i>Immunotherapy</i> Volume 16!","authors":"Rebecca Turner","doi":"10.2217/imt-2023-0309","DOIUrl":"10.2217/imt-2023-0309","url":null,"abstract":"","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-4"},"PeriodicalIF":2.8,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信